250 related articles for article (PubMed ID: 30472117)
1. Differences in the Conformational Energy Landscape of CDK1 and CDK2 Suggest a Mechanism for Achieving Selective CDK Inhibition.
Wood DJ; Korolchuk S; Tatum NJ; Wang LZ; Endicott JA; Noble MEM; Martin MP
Cell Chem Biol; 2019 Jan; 26(1):121-130.e5. PubMed ID: 30472117
[TBL] [Abstract][Full Text] [Related]
2. Targeting cyclin-dependent kinase 1 (CDK1) but not CDK4/6 or CDK2 is selectively lethal to MYC-dependent human breast cancer cells.
Kang J; Sergio CM; Sutherland RL; Musgrove EA
BMC Cancer; 2014 Jan; 14():32. PubMed ID: 24444383
[TBL] [Abstract][Full Text] [Related]
3. Inhibitors of Cyclin-Dependent Kinase 1/2 for Anticancer Treatment.
Mou J; Chen D; Deng Y
Med Chem; 2020; 16(3):307-325. PubMed ID: 31241436
[TBL] [Abstract][Full Text] [Related]
4. Discovery and evaluation of dual CDK1 and CDK2 inhibitors.
Payton M; Chung G; Yakowec P; Wong A; Powers D; Xiong L; Zhang N; Leal J; Bush TL; Santora V; Askew B; Tasker A; Radinsky R; Kendall R; Coats S
Cancer Res; 2006 Apr; 66(8):4299-308. PubMed ID: 16618755
[TBL] [Abstract][Full Text] [Related]
5. Cyclin-Dependent Kinase (CDK) Inhibitors: Structure-Activity Relationships and Insights into the CDK-2 Selectivity of 6-Substituted 2-Arylaminopurines.
Coxon CR; Anscombe E; Harnor SJ; Martin MP; Carbain B; Golding BT; Hardcastle IR; Harlow LK; Korolchuk S; Matheson CJ; Newell DR; Noble ME; Sivaprakasam M; Tudhope SJ; Turner DM; Wang LZ; Wedge SR; Wong C; Griffin RJ; Endicott JA; Cano C
J Med Chem; 2017 Mar; 60(5):1746-1767. PubMed ID: 28005359
[TBL] [Abstract][Full Text] [Related]
6. An integrated chemical biology approach provides insight into Cdk2 functional redundancy and inhibitor sensitivity.
Echalier A; Cot E; Camasses A; Hodimont E; Hoh F; Jay P; Sheinerman F; Krasinska L; Fisher D
Chem Biol; 2012 Aug; 19(8):1028-40. PubMed ID: 22921070
[TBL] [Abstract][Full Text] [Related]
7. Critical reanalysis of the methods that discriminate the activity of CDK2 from CDK1.
Sakurikar N; Eastman A
Cell Cycle; 2016 May; 15(9):1184-8. PubMed ID: 26986210
[TBL] [Abstract][Full Text] [Related]
8. Exploring the selectivity of a ligand complex with CDK2/CDK1: a molecular dynamics simulation approach.
Tripathi SK; Singh SK; Singh P; Chellaperumal P; Reddy KK; Selvaraj C
J Mol Recognit; 2012 Oct; 25(10):504-12. PubMed ID: 22996593
[TBL] [Abstract][Full Text] [Related]
9. CDK1 structures reveal conserved and unique features of the essential cell cycle CDK.
Brown NR; Korolchuk S; Martin MP; Stanley WA; Moukhametzianov R; Noble MEM; Endicott JA
Nat Commun; 2015 Apr; 6():6769. PubMed ID: 25864384
[TBL] [Abstract][Full Text] [Related]
10. Distinct properties of cyclin-dependent kinase complexes containing cyclin A1 and cyclin A2.
Joshi AR; Jobanputra V; Lele KM; Wolgemuth DJ
Biochem Biophys Res Commun; 2009 Jan; 378(3):595-9. PubMed ID: 19056339
[TBL] [Abstract][Full Text] [Related]
11. Rational design of potent GSK3beta inhibitors with selectivity for Cdk1 and Cdk2.
Lesuisse D; Dutruc-Rosset G; Tiraboschi G; Dreyer MK; Maignan S; Chevalier A; Halley F; Bertrand P; Burgevin MC; Quarteronet D; Rooney T
Bioorg Med Chem Lett; 2010 Mar; 20(6):1985-9. PubMed ID: 20167481
[TBL] [Abstract][Full Text] [Related]
12. Molecular models of cyclin-dependent kinase 1 complexed with inhibitors.
Canduri F; Uchoa HB; de Azevedo WF
Biochem Biophys Res Commun; 2004 Nov; 324(2):661-6. PubMed ID: 15474478
[TBL] [Abstract][Full Text] [Related]
13. Discovery of a novel class of 2-aminopyrimidines as CDK1 and CDK2 inhibitors.
Lee J; Kim KH; Jeong S
Bioorg Med Chem Lett; 2011 Jul; 21(14):4203-5. PubMed ID: 21684737
[TBL] [Abstract][Full Text] [Related]
14. 3D-QSAR CoMFA study on oxindole derivatives as cyclin dependent kinase 1 (CDK1) and cyclin dependent kinase 2 (CDK2) inhibitors.
Singh SK; Dessalew N; Bharatam PV
Med Chem; 2007 Jan; 3(1):75-84. PubMed ID: 17266627
[TBL] [Abstract][Full Text] [Related]
15. Distinct activation pathways confer cyclin-binding specificity on Cdk1 and Cdk2 in human cells.
Merrick KA; Larochelle S; Zhang C; Allen JJ; Shokat KM; Fisher RP
Mol Cell; 2008 Dec; 32(5):662-72. PubMed ID: 19061641
[TBL] [Abstract][Full Text] [Related]
16. Pre-clinical evaluation of cyclin-dependent kinase 2 and 1 inhibition in anti-estrogen-sensitive and resistant breast cancer cells.
Johnson N; Bentley J; Wang LZ; Newell DR; Robson CN; Shapiro GI; Curtin NJ
Br J Cancer; 2010 Jan; 102(2):342-50. PubMed ID: 20010939
[TBL] [Abstract][Full Text] [Related]
17. Selective chemical inhibition as a tool to study Cdk1 and Cdk2 functions in the cell cycle.
Krasinska L; Cot E; Fisher D
Cell Cycle; 2008 Jun; 7(12):1702-8. PubMed ID: 18583935
[TBL] [Abstract][Full Text] [Related]
18. Xylocydine, a novel Cdk inhibitor, is an effective inducer of apoptosis in hepatocellular carcinoma cells in vitro and in vivo.
Cho SJ; Lee SS; Kim YJ; Park BD; Choi JS; Liu L; Ham YM; Moon Kim B; Lee SK
Cancer Lett; 2010 Jan; 287(2):196-206. PubMed ID: 19616371
[TBL] [Abstract][Full Text] [Related]
19. Yeast as a model system to screen purine derivatives against human CDK1 and CDK2 kinases.
Mayi T; Facca C; Anne S; Vernis L; Huang ME; Legraverend M; Faye G
J Biotechnol; 2015 Feb; 195():30-6. PubMed ID: 25541464
[TBL] [Abstract][Full Text] [Related]
20. Development of CDK2 and CDK5 Dual Degrader TMX-2172.
Teng M; Jiang J; He Z; Kwiatkowski NP; Donovan KA; Mills CE; Victor C; Hatcher JM; Fischer ES; Sorger PK; Zhang T; Gray NS
Angew Chem Int Ed Engl; 2020 Aug; 59(33):13865-13870. PubMed ID: 32415712
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
